HIV-positive-to-HIV-positive kidney transplantation-results at 3 to 5 years

New England Journal of Medicine

Volumn 372, Issue 7, 2015, Pages 613-620

  Muller, Elmi ^a   Barday, Zunaid ^a   Mendelson, Marc ^a   Kahn, Delawir ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DONOR SELECTION; DOSE RESPONSE; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VIRUS DETECTION; VIRUS LOAD; ALLOGRAFT; ANTIBIOTIC PROPHYLAXIS; COMPLICATION; DISEASE COURSE; DONOR; FOLLOW UP; GRAFT REJECTION; HIV SEROPOSITIVITY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RENAL INSUFFICIENCY, CHRONIC; SOUTH AFRICA;

ADULT; ALLOGRAFTS; ANTI-RETROVIRAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HIV SEROPOSITIVITY; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY, CHRONIC; SOUTH AFRICA; TISSUE DONORS;

EID: 84922736857     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1408896     Document Type: Article

References (29)

1. Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathologi-cal and follow-up study. Kidney Int 1999; 56:2203-13.
2. Okpechi I, Swanepoel C, Duffield M, et al. Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. Nephrol Dial Transplant 2011;26:1853-61.
3. Wearne N, Swanepoel CR, Boulle A, Duffield MS, Rayner BL. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant 2012; 27:4109-18.
4. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008;197:1548-57.
5. Winston J, Deray G, Hawkins T, Sz-czech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008;47:1449-57.
6. Wyatt CM, Winston J. Renal disease in patients with HIV. Curr Infect Dis Rep 2006;8:76-81.
7. Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007; 21:2101-3.
8. Peters PJ, Moore DM, Mermin J, et al. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 2008;74:925-9.
9. Mulenga LB, Kruse G, Lakhi S, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on anti-retroviral therapy in Lusaka, Zambia. AIDS 2008;22:1821-7.
10. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003;75:425-9.
11. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007;84:563-71.
12. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010;362:2336-7.
13. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12:563-70.
14. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010;363:2004-14.
15. Erratum, N Engl J Med 2011;364:1082.
16. Waters L, Smit E. HIV-1 superinfec-tion. Curr Opin Infect Dis 2012;25:42-50.
17. Streeck H, Li B, Poon AF, et al. Immune-driven recombination and loss of control after HIV superinfection. J Exp Med 2008;205:1789-96.
18. Canaud G, Dejucq-Rainsford N, Avet-tand-Fenoël V, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol 2014;25:407-19.
19. Jacobs GB, Laten A, van Rensburg EJ, et al. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retro-viruses 2008;24:1009-12.
20. Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V. Resistance to antiretro-viral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol 2011;83:1508-13.
21. Nwobegahay JM, Bessong PO, Masebe TM, Mavhandu LG, Iweriebor BC, Selabe G. Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa. J Health Popul Nutr 2011;29:303-9.
22. Nwobegahay J, Selabe G, Ndjeka NO, Manhaeve C, Bessong PO. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa. J Med Virol 2012;84:1839-43.
23. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009;49:1928-35.
24. Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012;7(3):e32144.
25. Levison JH, Wood R, Scott CA, et al. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis 2013;56: 587-97.
26. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cyto-chrome P4503A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304.
27. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cyto-chrome P4503A4. Curr Drug Metab 2008; 9:310-22.
28. Iordanskiy S, Santos S, Bukrinsky M. Nature, nurture and HIV: the effect of producer cell on viral physiology. Virology 2013;443:208-13.
29. Fenner L, Reid SE, Fox MP, et al. Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. Trop Med Int Health 2013;18:194-8.